A Phase Iia Prospective, Open-label, Multicenter Study To Determine The Pharmacokinetics (pk) And Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) For The Treatment Of Complicated Intra-abdominal Infections (Ciais) In Hospitalized Adults

Trial Profile

A Phase Iia Prospective, Open-label, Multicenter Study To Determine The Pharmacokinetics (pk) And Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) For The Treatment Of Complicated Intra-abdominal Infections (Ciais) In Hospitalized Adults

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Avibactam/aztreonam (Primary) ; Metronidazole
  • Indications Intra-abdominal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms REJUVENATE
  • Sponsors AstraZeneca; Pfizer
  • Most Recent Events

    • 16 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
    • 16 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
    • 16 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top